2024
1.Nakamura K*, Yaguchi T* (*equally contributed), Murata M, Ota Y, Mikoshiba A, Kiniwa, Okuyama R, Kawakami Y. Tumor eradication by triplet therapy with BRAF inhibitor, TLR 7 agonist, and PD-1 antibody for BRAF mutated melanoma. Cancer Sci 2024, in press.
2.Singh VP, Hirose S, Takemoto M, Farrag A M.A.S., Sato S, Honjo T, Chamoto K*, Uesugi M* (*equally corresponding). Chemoproteomic Identification of Spermidine-Binding Proteins and Antitumor-Immunity Activators. J Am Chem Soc 2024, in press.
3.Katada C, Yokoyama T, Watanabe A, Hara H, Yoshii T, Fujii H, Yamaguchi H, Nakajima TE, Izawa N, Ando T, Nomura M, Kojima T, Yamashita K, Kawakami S, Ishiyama H, Inoue Y, Sakamoto Y, Sasaki H, Ishikawa H, Hosokawa A, Hamamoto Y, Muto M, Tahara M, Koizumi W. Optimizing Organ-Preservation Strategies Through Chemotherapy-Based Selection in Esophageal Squamous Cell Carcinoma: Results From the CROC Multi-Institutional Phase 2 Clinical Trial. Int J Radiat Oncol Biol Phys 2024, in press.
4.Fujii S, Katada C, Watanabe H, Shimoda T, Ochiai A, Yokoyama T, Sakamoto Y, Kano K, Ichinoe M, Nemoto T, Fujita M, Tateishi Y, Sugiura H, Mikami T, Yano T, Kato T, Muto M, Hayashi R.Tumor thickness as a novel risk factor for lymph node metastasis by superficial squamous cell carcinoma of head and neck. Cancer Sci 2024, in press.
5.Kadota T, Abe S, Uedo N, Doyama H, Furue Y, Muto M, Nonaka S, Takamaru H, Murano T, Nakajo K, Tani Y, Okubo Y, Kawasaki A, Yoshida N, Watanabe A, Katada C, Tamaoki M, Yokoyama A, Furuya H, Ikeno T, Wakabayashi M, Yano T. Comparison of Effective Imaging Modalities for Detecting Gastric Neoplasms: A Randomized 3-Arm Phase II Trial. Am J Gastroenterol 2024, in press.
6.Mitani Y, Hirohashi K, Tamaoki M, Yokoyama A, Katada C, Ueda A, Yamahigashi N, Higuchi H, Muto M. Efficacy and safety of radial incision and cutting for nonsurgical refractory benign esophageal stricture. Endosc Int Open 2024, in press.
7.Hayashi H*, Chamoto K* (*equally contributed), Hatae R, Kurosaki T, Togashi Y, Fukuoka K, Goto M, Chiba Y, Tomida S, Ota T, Haratani K, Takahama T, Tanizaki J, Yoshida T, Iwasa T, Tanaka K, Takeda M, Hirano T, Yoshida H, Ozasa H, Sakamori Y, Sakai K, Higuchi K, Uga H, Suminaka C, Hirai T, Nishio K, Nakagawa K, Honjo T. Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade. J Clin Invest 134: e168318, 2024.
8.Sugi T, Katoh Y, Ikeda T, Seta D, Iwata T, Nishio H, Sugawara M, Kato D, Katoh K, Kawana K, Yaguchi T, Kawakami Y, Hirai S. SCD1 inhibition enhances the effector functions of CD8+ T cells via ACAT1 dependent reduction of esterified cholesterol. Cancer Sci 115: 48-58, 2024.
9.Chamoto K, Zhang B, Tajima M, Honjo T, Fagarasan S. Spermidine - an old molecule with a new age-defying immune function. Trends Cell Biol 34; 363-370, 2024.
10.Uneno Y, Nomura M, Hosokai T, Kurakake Y, Fuki M, Shiomi H, Tamaoki M, Yokoyama A, Katada C, Muto M. Successful management of malignant pericarditis using nivolumab for metastatic esophageal squamous cell carcinoma: a case report. Internal Medicine 63: 677-680, 2024.
11.Minatogawa H, Izawa N, Shimomura K, Arioka H, Iihara H, Sugawara M, Morita H, Mochizuki A, Nawata S, Mishima K, Tsuboya A, Miyaji T, Honda K, Yokomizo A, Hashimoto N, Yanagihara T, Endo J, Kawaguchi T, Furuya N, Sone Y, Inada Y, Ohno Y, Katada C, Hida N, Akiyama K, Ichikura D, Konomatsu A, Ogura T, Yamaguchi T, Nakajima TE. Dexamethasone-sparing on days 2-4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial). Br J Cancer 130: 224-232, 2024.
12.Hori K, Katada C, Okada H, Katagiri A, Matsuo Y, Yokoyama T, Yano T, Suzuki H, Shimizu Y, Furue Y, Nakanishi H, Koike T, Takizawa K, Hirao M, Yoshii T, Yamanouchi T, Kawakubo H, Kobayashi N, Shimoda T, Ochiai A, Ishikawa H, Yokoyama A, Muto M. Association between continuous cessation or reduction of drinking alcohol and improvement of multiple dysplastic lesions in patients with esophageal squamous cell carcinoma after endoscopic resection. Esophagus 21: 31-40, 2024.
13.Yano T, Hayashi Y, Ishihara R, Iijima K, Iwakiri K, Uesato M, Oyama T, Katada C, Kawada K, Kushima R, Tateishi Y, Fujii S, Manabe N, Minami H, Kawakubo H, Tsubosa Y, Yamamoto S, Kadota T, Minashi K, Takeuchi H, Doki Y, Muto M. Remarkable response as a new indicator for endoscopic evaluation of local efficacy of non-surgical treatments for esophageal cancer. Esophagus 21: 85-94, 2024.
14.Hirata K, Yoshida K, Katada C, Watanabe A, Tsushima T, Yamaguchi T, Yamamoto S, Ishikawa H, Sato Y, Imamura CK, Tanigawara Y, Ito Y, Kato K, Kitagawa Y, Hamamoto Y. Definitive chemoradiotherapy with paclitaxel for locally advanced esophageal squamous cell carcinoma in older patients (PARADISE-1): a phase I trial. BMC Cancer 24: 873, 2024.
2023
1.Chamoto K*, Yaguchi T*, Tajima M* (*equally contributed), Tajima M, Honjo T. Insights from 30-year journey: function, regulation and therapeutic modulation of PD1. Nat Rev Immnol 23: 682-695, 2023.
2.Chamoto K, Gibney BC, Wagner WL, Ackermann M, Khalil HA, Mentzer SJ. Vascularization of the adult mouse lung grafted onto the chick chorioallantoic membrane. Microvasc Res 151: 104596, 2023.
3.Kurosaki T, Chamoto K, Suzuki S, Kanemura H, Mitani S, Tanaka K, Kawakami H, Kishimoto Y, Haku Y, Ito K, Sato T, Suminaka C, Yamaki M, Chiba Y, Yaguchi T, Omori K, Kobayashi T, Nakagawa K, Honjo T, Hayashi H. The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study. Front Immunol 14:1325462, 2023.
4.Tanizaki J, Kuroda H, Yokoyama T, Takahama M, Shoda H, Nakamura A, Kitamura Y, Mamesaya N, Kadota Y, Sawa K, Okishio K, Okada M, Suminaka C, Noda K, Sakai K, Chiba Y, Nishio K, Chamoto K, Honjo T, Yamamoto N, Nakagawa K, Hayashi H. Lack of Association of Plasma Levels of Soluble Programmed Cell Death Protein 1, Programmed Death-Ligand 1, and CTLA-4 With Survival for Stage II to IIIA NSCLC After Complete Resection and Adjuvant Chemotherapy. JTO Clin Res Rep 4:100590, 2023.
5.Kawakami H, Sunakawa Y, Inoue E, Matoba R, Noda K, Sato T, Suminaka C, Yamaki M, Sakamoto Y, Kawabata R, Ishiguro A, Akamaru Y, Kito Y, Yabusaki H, Matsuyama J, Takahashi M, Makiyama A, Hayashi H, Chamoto K, Honjo T, Nakagawa K, Ichikawa W, Fujii M. Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial. Eur J Cancer 184: 10-20, 2023.
6.Zou Y, Yaguchi T. Programmed cell death-1 blockade therapy in melanoma: Resistance mechanisms and combination strategies. Exp Dermatol 32: 264-275, 2023.
7.Katada C, Yokoyama T, Hirasawa D, Iizuka T, Kikuchi D, Yano T, Honbu T, Yoshio T, Yoshimizu S, Ono H, Yabuuchi Y, Terai S, Hashimoto S, Takahashi K, Tanaka S, Urabe Y, Arima M, Tanabe S, Wada T, Furue Y, Oyama T, Takahashi A, Sakamoto Y, Muto M. Curative management after endoscopic resection for esophageal squamous cell carcinoma invading muscularis mucosa or shallow submucosal layer – multicenter real-world survey in Japan. Am J Gastoenterol 118: 1175-1183, 2023.
8.Katada C, Yokoyama T, Mure K, Doyama H, Nakanishi H, Shimizu Y, Yamamoto K, Furue Y, Tamaoki M, Koike T, Kawahara Y, Kiyokawa H, Konno M, Yokoyama A, Ohashi S, Ishikawa H, Yokoyama A, Muto M. Risk factors for the development of second primary esophageal squamous-cell carcinoma after endoscopic resection for esophageal squamous-cell carcinoma according to genetic polymorphisms related to alcohol and nicotine metabolism. Jpn J Clin Oncol 53: 774-780, 2023.
9.Katada C, Yokoyama T, Yano T, Suzuki H, Furue Y, Yamamoto K, Doyama H, Koike T, Tamaoki M, Kawata N, Hirao M, Kawahara Y, Ogata T, Katagiri A, Yamanouchi T, Kiyokawa H, Kawakubo H, Konno M, Yokoyama A, Ohashi S, Kondo Y, Kishimoto Y, Kano K, Mure K, Hayashi R, Ishikawa H, Yokoyama A, Muto M. Alcohol Consumption, Multiple Lugol-voiding Lesions, and Field Cancerization. DEN Open 4, e261, 2023.
10.Hirao M, Katada C, Yokoyama T, Yano T, Suzuki H, Furue Y, Yamamoto K, Doyama H, Koike T, Tamaoki M, Kawata N, Kawahara Y, Katagiri A, Ogata T, Yamanouchi T, Kiyokawa H, Kawakubo H, Konno K, Ishikawa H, Yokoyama A, Muto M. Metachronous primary gastric cancer after endoscopic resection in patients with esophageal squamous cell carcinoma. Gastic Cancer 26: 988-1001, 2023.
11.Inoue T, Katada C, Shimizu T, Nikaido M, Higuchi H, Kishimoto Y, Muto M. Endoscopic resection combination with gel immersion and curved laryngoscope for superficial hypopharyngeal cancer. Endoscopy 55: E831-832, 2023.
12.Ishido K, Tanabe S, Katada C, Ishibashi Y, Kitahara G, Onoue M, Kubota Y, Furue Y, Wada T, Watanabe A, Kusano C. Evaluation of Prognostic Factors for Unresectable or Recurrent Gastric Cancer Treated with Nivolumab. J Gastrointest Cancer 54: 485-491, 2023.
13.Nomura M, Hosokai T, Tamaoki M, Yokoyama A, Matsumoto S, Muto M. Timing of the infusion of nivolumab for patients with recurrent or metastatic squamous cell carcinoma of the esophagus influences its efficacy. Esophagus 20: 722-731, 2023.
14.Kondo T, Kanai M, Matsubara J, Yamaguchi D, Ura T, Kou T, Itani T, Nomura M, Funakoshi T, Yokoyama A, Doi K, Tamaoki M, Yoshimura M, Uza N, Yamada T, Masui T, Minamiguchi S, Matsumoto S, Ishikawa H, Muto M. Association between homologous recombination gene variants and efficacy of oxaliplatin-based chemotherapy in advanced pancreatic cancer: prospective multicenter observational study. Med Oncol 40: 144, 2023.
15.Nguyen Vu TH, Kikuchi O, Ohashi S, Saito T, Ida T, Nakai Y, Cao Y, Yamamoto Y, Kondo Y, Mitani Y, Kataoka S, Kondo T, Katada C, Yamada A, Matsubara J, Muto M. Combination therapy with WEE1 inhibition and trifluridine/tipiracil against esophageal squamous cell carcinoma. Cancer Sci 114: 4664-4676, 2023.
2022
1.Tanaka K*, Chamoto K* (*equally corresponding), Saeki S, Hatae R, Ikematsu Y, Sakai K, Ando N, Sonomura K, Kojima S, Taketsuna M, Kim YH, Yoshida H, Ozasa H, Sakamori Y, Hirano T, Matsuda F, Hirai T, Nishio K, Sakagami T, Fukushima M, Nakanishi Y, Honjo T, Okamoto I. Combination bezafibrate and nivolumab treatment of patients with advanced non–small cell lung cancer. Sci Transl Med 14 (675): eabq0021, 2022.
2.Matsushima S, Ajiro M, Iida K, Chamoto K, Honjo T, Hagiwara M. Chemical induction of splice-neoantigens attenuates tumor growth. Sci Transl Med 14 (673): eabq6056, 2022.
3.Al-Habsi M*, Chamoto K*, Matsumoto K*, Nomura N* (*equally contributed), Zhang B, Sugiura Y, Sonomura K, Maharani A, Nakajima Y, Wu Y, Nomura Y, Menzies R, Tajima M, Kitaoka K, Haku Y, Delghandi S, Yurimoto K, Matsuda F, Iwata S, Ogura T, Fagarasan S, Honjo T. Spermidine activates mitochondrial trifunctional protein and improves antitumor immunity in mice. Science 28; 378 (6618): eabj3510, 2022.
4.Katoh Y, Yaguchi T* (*equally corresponding), Kubo A, Iwata T, Morii K, Kato D, Ohta S, Satomi R, Yamamoto Y, Oyamada Y, Ouchi K, Takahashi S, Ishioka C, Matoba R, Suematsu M, Kawakami Y. Inhibition of stearoyl-CoA desaturase 1 (SCD1) enhances the antitumor T cell response through regulating β-catenin signaling in cancer cells and ER stress in T cells and synergizes with anti-PD-1 antibody. J Immunother Cancer 10: e004616, 2022.
5.Muto M, Katada C, Yokoyama T, Yano T, Oda I, Ezoe Y, Tanabe S, Shimizu Y, Doyama H, Koike T, Takizawa K, Hirao M, Okada H, Ogata T, Katagiri A, Yamanouchi T, Matsuo Y, Kawakubo H, Omori T, Kobayashi N, Shimoda T, Ochiai A, Ishikawa H, Baba K, Amanuna Y, Yokoyama A, Ohashi S, Yokoyama A. Field effect of alcohol, cigarette smoking and their cessation on the development of multiple dysplastic lesions and squamous cell carcinoma: Long term multicenter cohort study. Gastro Hep Advances 1: 265-276, 2022.
6.Ishihara R, Katada C. History of endoscopic diagnosis and treatment for esophageal and pharyngeal squamous cell carcinoma. Dig Endosc Suppl 2: 23-26, 2022.
7.Saito Y, Kodashima S, Matsuda T, Matsuda K, Fujishiro M, Tanaka K, Kobayashi K, Katada C, Horimatsu T, Muto M, Ohtsuka K, Oda I, Kato M, Kida M, Hoteya S, Yamamoto H, Ryozawa S, Iwakiri R, Kutsumi H, Kato M, Haruma K, Fujimoto K, Iishi H, Ogata H, Uemura N, Kaminishi M, Tajiri H, Inoue H. Current status of diagnostic and therapeutic colonoscopy in Japan: The Japan Endoscopic Database Project. Digestive Endoscopy 34: 144-152, 2022.
8.Yamamoto Y, Yoshida N, Yano T, Horimatsu T, Uedo N, Kawata N, Kanzaki H, Hori S, Yao K, Abe S, Katada C, Yokoi C, Ohata K, Doyama H, Yoshimura K, Ishikawa H, Muto M. Assessment of Outcomes From 1-Year Surveillance After Detection of Early Gastric Cancer Among Patients at High Risk in Japan. JAMA Netw Open 5: e2227667, 2022.
9.Oikawa J, Fukaya H, Wada T, Kishihara J, Sato T, Matsuura G, Nakamura H, Ishizue N, Katada C, Tanabe S, Niwano S, Kusano C, Ako J. Esophagogastric complications in radiofrequency and cryoballoon catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 33: 1160-1166, 2022.
10.Yoshio T, Minashi K, Mizusawa J, Morita Y, Tajika M, Fujiwara J, Yamamoto Y, Katada C, Hori S, Yano T, Takizawa K, Fukuda H, Muto M. Effect of chemoradiation on the development of second primary cancers after endoscopic resection of T1 esophageal squamous cell carcinoma. Esophagus 19: 469-476, 2022.